These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38205538)

  • 1. Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients.
    Khwaja J; Ravichandran S; Bomsztyk J; Cohen O; Foard D; Martinez-Naharro A; Venneri L; Fontana M; Hawkins PN; Gillmore J; Lachmann HJ; Mahmood S; Whelan C; Kirkwood AA; Wechalekar A
    Haematologica; 2024 May; 109(5):1598-1602. PubMed ID: 38205538
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
    Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
    J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.
    Lilleness B; Ruberg FL; Mussinelli R; Doros G; Sanchorawala V
    Blood; 2019 Jan; 133(3):215-223. PubMed ID: 30333122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional amyloid distribution and impact on mortality in light-chain amyloidosis: a T1 mapping cardiac magnetic resonance study.
    Wan K; Li W; Sun J; Xu Y; Wang J; Liu H; Dong Y; Cheng W; Zhang Q; Zeng Z; Zhou X; Han Y; Chen Y
    Amyloid; 2019 Mar; 26(1):45-51. PubMed ID: 30931628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local vs. systemic pulmonary amyloidosis-impact on diagnostics and clinical management.
    Baumgart JV; Stuhlmann-Laeisz C; Hegenbart U; Nattenmüller J; Schönland S; Krüger S; Behrens HM; Röcken C
    Virchows Arch; 2018 Nov; 473(5):627-637. PubMed ID: 30136180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
    Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival.
    Ozga M; Zhao Q; Benson D; Elder P; Williams N; Bumma N; Rosko A; Chaudhry M; Khan A; Devarakonda S; Kahwash R; Vallakati A; Campbell C; Parikh SV; Almaani S; Prosek J; Bittengle J; Pfund K; LoRusso S; Freimer M; Redder E; Efebera Y; Sharma N
    Cancer Med; 2021 Feb; 10(3):965-973. PubMed ID: 33347707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement.
    Oubari S; Naser E; Papathanasiou M; Luedike P; Hagenacker T; Thimm A; Rischpler C; Kessler L; Kimmich C; Hegenbart U; Schönland S; Rassaf T; Reinhardt HC; Jöckel KH; Dürig J; Dührsen U; Carpinteiro A
    Eur J Haematol; 2021 Oct; 107(4):449-457. PubMed ID: 34185342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis.
    Hwa YL; Gertz MA; Kumar SK; Lacy MQ; Buadi FK; Dingli D; Kapoor P; Zeldenrust SR; Leung N; Hayman SR; Gonsalves WI; Kourelis TV; Warsame R; Go RS; Muchtar E; Hobbs MA; Fonder AL; Russell S; Kyle RA; Rajkumar SV; Dispenzieri A
    Leukemia; 2019 May; 33(5):1268-1272. PubMed ID: 30737485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy　- A Single-Center Cohort Study of 227 Patients.
    Feng J; Zhang C; Shen K; Sun J; Fang Q; Zhang L; Cao X; Zhou D; Li J; Tian Z
    Circ J; 2019 Mar; 83(4):775-782. PubMed ID: 30773521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.
    Sidiqi MH; Aljama MA; Jevremovic D; Morice WG; Timm M; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Gonsalves WI; Kumar S; Kapoor P; Kourelis T; Leung N; Hogan WJ; Gertz M
    Haematologica; 2018 Jul; 103(7):1229-1234. PubMed ID: 29674497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis.
    Milani P; Dispenzieri A; Scott CG; Gertz MA; Perlini S; Mussinelli R; Lacy MQ; Buadi FK; Kumar S; Maurer MS; Merlini G; Hayman SR; Leung N; Dingli D; Klarich KW; Lust JA; Lin Y; Kapoor P; Go RS; Pellikka PA; Hwa YL; Zeldenrust SR; Kyle RA; Rajkumar SV; Grogan M
    Circ Cardiovasc Imaging; 2018 May; 11(5):e006588. PubMed ID: 29752392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in Japan.
    Fuchida SI; Ide D; Taminishi-Katsuragawa Y; Suga T; Matsui-Maegawa S; Maruyama N; Iwamura Y; Kitamura Y; Okawa Y; Okano A; Hatsuse M; Murakami S; Shimazaki C
    Int J Hematol; 2020 Jun; 111(6):803-811. PubMed ID: 32020505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis.
    Acevedo J; Doros G; Szalat R; Sanchorawala V
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):425-426. PubMed ID: 33622658
    [No Abstract]   [Full Text] [Related]  

  • 15. Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016.
    Rutten KHG; Raymakers RAP; Hazenberg BPC; Nienhuis HLA; Vellenga E; Minnema MC
    Amyloid; 2018 Dec; 25(4):227-233. PubMed ID: 30513220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the Boston University staging system in AL amyloidosis.
    Tomlinson R; Matigian N; Mollee P
    Amyloid; 2019 Sep; 26(3):125-127. PubMed ID: 31145007
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis.
    Tandon N; Sidana S; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Kyle RA; Buadi FK; Dingli D; Hayman SR; Fonder AL; Hobbs MA; Gonsalves WI; Kapoor P; Hwa YL; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Kumar SK
    Amyloid; 2017 Sep; 24(3):183-188. PubMed ID: 28699793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.
    Rezk T; Lachmann HJ; Fontana M; Naharro AM; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Hawkins PN; Gillmore JD
    Br J Haematol; 2019 Aug; 186(3):460-470. PubMed ID: 31124579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation.
    Havasi A; Stern L; Lo S; Sun F; Sanchorawala V
    Am J Hematol; 2016 Oct; 91(10):E458-60. PubMed ID: 27356490
    [No Abstract]   [Full Text] [Related]  

  • 20. Left ventricular myocardial work improves in response to treatment and is associated with survival among patients with light chain cardiac amyloidosis.
    Briasoulis A; Bampatsias D; Petropoulos I; Rempakos A; Patras R; Theodorakakou F; Makris N; Dimopoulos MA; Stamatelopoulos K; Kastritis E
    Eur Heart J Cardiovasc Imaging; 2024 Apr; 25(5):698-707. PubMed ID: 38142437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.